Quantcast

Latest Regado Biosciences Inc. Stories

2014-08-11 16:28:29

Conference Call and Webcast, August 12, 2014, at 8:30 a.m. EDT BASKING RIDGE, N.J., Aug. 11, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced its second quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results will be held...

2014-07-29 16:27:56

BASKING RIDGE, N.J., July 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that it will hold a conference call and live audio webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to discuss its second quarter 2014 financial results and corporate highlights....

2014-07-14 20:21:19

SAN DIEGO & BASKING RIDGE, N.J., July 14, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Regado Biosciences, Inc. (NASDAQ: RGDO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between August 22, 2013 and July 9, 2014 (the "Class...

2014-07-09 16:28:44

BASKING RIDGE, N.J., July 9, 2014 /PRNewswire/ -- Regado Biosciences, Inc., (NASDAQ: RGDO) today announced that, further to their decision to voluntarily pause enrollment in their REGULATE-PCI trial, the United States Food and Drug Administration (FDA) informed the company today that a clinical hold has been placed on all patient enrollment and dosing of either study drug in the ongoing Phase 3 REGULATE-PCI trial. According to the FDA, this action was taken to formalize the...

2014-07-02 20:21:45

BASKING RIDGE, N.J., July 2, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that the Data Safety Monitoring Board (DSMB) has initiated an unplanned review of data from the REGULATE-PCI trial. Patient enrollment has been paused until the DSMB has completed its...

2014-06-23 08:27:50

Phase 1 Clinical Data Highlights Factor IXa as an Excellent Target for Anticoagulation Therapy BASKING RIDGE, N.J., June 23, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the discovery and development of actively controllable aptamer therapeutics for the acute care setting, today announced the publication in the Journal of Thrombosis and Thrombolysis of data from a single escalating-dose Phase 1 clinical trial of the REG2...

2014-06-18 08:28:25

BASKING RIDGE, N.J., June 18, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (also known as REG1), its first-in-class, actively controllable injectable antithrombotic drug system, today announced the appointment of Drew Fromkin to the company's Board of Directors. Mr. Fromkin most recently served as President, Chief Executive Officer, of Clinical Data, Inc., prior to its...

2014-05-29 08:29:09

BASKING RIDGE, N.J., May 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that it will present at the Jefferies 2014 Global Healthcare Conference at 10 a.m. EDT on June 5, 2014, in New York City. A live audio webcast of the presentation will be available under the...

2014-05-19 08:27:44

BASKING RIDGE, N.J., May 19, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced the appointment of Nicholas Pelliccione, Ph.D., as Senior Vice President of Regulatory Affairs and Quality Assurance. He succeeds Alexander Giaquinto, Ph.D., who has served as Regado's Senior...

2014-05-14 08:30:11

Conference Call and Webcast, May 14, 2014, at 8:30 a.m. EDT BASKING RIDGE, N.J., May 14, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the Revolixys(TM) Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced its first quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related